CD274 and non-small cell lung carcinoma: Platinum-based, definitive concurrent chemoradiotherapy (CRT) followed by consolidation anti-PD-L1 (durvalumab, 10 mg/kg every 2 weeks or 1500 mg every 4 weeks), is the guideline-recommended treatment in patients with locally advanced unresectable non-small cell lung cancer (NSCLC).6 A potential upregulation of tumor PD-L1 expression during chemotherapy and radiotherapy, supports the hypothesis that adding durvalumab from the start of CRT onwards could act synergistically with CRT.